Affected person 1, a boy born to consanguineous Lebanese parents, presented at three months old with respiratory syncytial virus bronchiolitis, followed by recurrent episodes of pneumonia. At 5 months old, severe T-cell lymphopenia and markedly reduced in vitro T-cell proliferation were observed . He was well and had not been getting intravenous immune globulin replacement therapy 13 several weeks after undergoing HSCT. In the first 24 months of life, Patient 2, a girl born to nonconsanguineous Finnish parents, had recurrent otitis press, pneumonia, diarrhea, and three episodes of thrombocytopenia that resolved spontaneously. At 2. Several months afterwards, computed tomography of the chest showed a fresh pulmonary infiltrate . A lung biopsy revealed granulomatous irritation with acid-fast bacilli.announced today that it provides initiated a study to verify the efficacy of AEOL 10150 as a countermeasure to nuclear and radiological exposure in non-human primates. AEOL 10150 has previously demonstrated a statistically significant survival advantage when given to mice after contact with radiation. The new study is designed to check the efficacy of AEOL 10150 as cure for harm to the lungs because of exposure to radiation and to begin establishing an pet model which can be validated and could be utilized by the U.S. The new research builds on results from previous research in rats and mice where it had been shown that doses in the range of 5 to 30 mg/kg AEOL 10150 given daily up to 24 hrs after irradiation and administered for provided that 10 weeks mitigate useful lung damage in rats and led to a statistically significant survival benefit in mice.